A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)
Pfizer
Summary
This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Eligible participants for this study include: * adults aged 18 years or older with * obesity (BMI of 30.0 kg/m2 to 50.0 kg/m2) or with * overweight (BMI of 27.0 kg/m2 to \<30.0 kg/m2) who also have at least 1 prespecified weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea), at the screening visit. Exclusion Criteria: Participants who are not eligible include those with diabetes mellitus, a body weight change of \>5% or use of weight loss medications in the 12 weeks prior to screening, a history of or plan for surgi…
Interventions
- DrugPF-08653945
Subcutaneous Injection
- DrugPF-08653944
Subcutaneous Injection
- DrugPlacebo
Subcutaneous Injection
Locations (3)
- Ark Clinical ResearchFountain Valley, California
- Paragon Rx ClinicalGarden Grove, California
- Koch Family Medicine Clinical Research/Elite Research NetworkMorton, Illinois